Hospital
Sutter Valley Hospitals
Sutter Valley Hospitals was paid $20.04M by Medicaid between Jan 2018 and Dec 2024, across 158 billing codes. Its largest line is 99281, Emergency department visit for the evaluation and management, self-limited or minor — 21% of everything it billed.
33Billing provider infoSUTTER VALLEY HOSPITALS
DAVIS, CA 95616
DAVIS, CA 95616
33aNPI1770532608assigned 05/08/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$20.04M
24GClaims398,782
24DCodes billed158
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#120 of 410
Median peer was paid$6.90M
This provider vs. median2.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 53,969 | $2.37M | |
| 2019 | 53,275 | $2.27M | |
| 2020 | 46,596 | $2.14M | |
| 2021 | 59,065 | $2.88M | |
| 2022 | 73,151 | $3.82M | |
| 2023 | 56,497 | $2.92M | |
| 2024incomplete | 56,229 | $3.64M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 21% | 30,640 | 26,947 | $4.22M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 34,702 | 30,194 | $3.20M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 7.0% | 2,830 | 2,739 | $1.41M |
| 70450 | Computed tomography, head or brain; without contrast material | 4.7% | 3,256 | 3,160 | $948K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.4% | 7,692 | 6,978 | $891K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 3.9% | 3,404 | 2,314 | $773K |
| 0450 | Emergency room services | 3.0% | 7,575 | 6,766 | $600K |
| 96375 | Therapeutic injection; each additional sequential IV push | 3.0% | 6,898 | 6,016 | $596K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.6% | 9,115 | 8,448 | $523K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.3% | 3,160 | 2,736 | $470K |
| 99201 | 2.2% | 2,543 | 1,690 | $433K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.1% | 2,918 | 2,687 | $431K |
146 more codes
| 71046 | Radiologic examination, chest; 2 views | 1.7% | 7,757 | $340K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.4% | 5,410 | $288K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.3% | 3,756 | $265K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 1,056 | $263K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 4,131 | $249K |
| 99199 | Unlisted special service, procedure or report | 1.2% | 2,470 | $243K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.2% | 4,327 | $231K |
| J3490 | Unclassified drugs | 1.1% | 38,706 | $226K |
| 80053 | Comprehensive metabolic panel | 1.0% | 19,741 | $207K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,698 | $173K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 23,000 | $165K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,223 | $161K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,128 | $149K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 271 | $145K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 793 | $120K |
| Z7502 | <1% | 2,923 | $109K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 730 | $101K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 4,697 | $93K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,235 | $74K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 139 | $70K |
| 84484 | <1% | 6,878 | $66K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,082 | $64K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,194 | $64K |
| 83690 | <1% | 8,896 | $59K | |
| 73610 | <1% | 932 | $58K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,162 | $57K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,213 | $51K |
| 93971 | <1% | 183 | $49K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 558 | $49K |
| 82077 | <1% | 1,440 | $47K | |
| 83880 | <1% | 1,446 | $44K | |
| 73630 | <1% | 732 | $43K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,252 | $40K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,044 | $39K |
| 81025 | <1% | 8,854 | $39K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,684 | $39K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,034 | $39K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,330 | $38K |
| 76801 | <1% | 291 | $36K | |
| 99284 | Emergency room visit (serious) | <1% | 80 | $35K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,197 | $34K |
| 87040 | <1% | 2,646 | $33K | |
| 81001 | <1% | 6,744 | $33K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 72 | $32K |
| 76830 | Ultrasound, transvaginal | <1% | 191 | $28K |
| 82803 | <1% | 1,892 | $27K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 174 | $27K |
| 80143 | <1% | 597 | $25K | |
| 0270 | <1% | 954 | $23K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,433 | $23K |
| 73130 | <1% | 375 | $23K | |
| 80179 | <1% | 590 | $23K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,910 | $22K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,038 | $21K |
| 83605 | <1% | 2,250 | $21K | |
| 73030 | <1% | 325 | $21K | |
| 85379 | <1% | 2,028 | $21K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,136 | $20K |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 1,003 | $19K |
| 83735 | <1% | 3,090 | $19K | |
| 73110 | <1% | 293 | $18K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,273 | $17K |
| 81015 | <1% | 4,301 | $17K | |
| 70486 | <1% | 39 | $17K | |
| 81003 | <1% | 6,471 | $16K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,816 | $15K |
| 59025 | Fetal non-stress test | <1% | 262 | $15K |
| 87077 | <1% | 1,679 | $14K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,272 | $14K |
| 87186 | <1% | 1,584 | $14K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 176 | $12K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,738 | $12K |
| 99499 | <1% | 151 | $11K | |
| 87430 | <1% | 1,047 | $11K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,217 | $11K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,712 | $11K |
| 82330 | <1% | 597 | $10K | |
| 87400 | <1% | 1,088 | $10K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 16 | $10K |
| 74018 | <1% | 210 | $10K | |
| 85730 | <1% | 1,912 | $10K | |
| 73560 | <1% | 235 | $10K | |
| 87081 | <1% | 1,121 | $10K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,595 | $10K |
| 72100 | <1% | 129 | $9K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,138 | $9K |
| 85610 | <1% | 2,502 | $9K | |
| 0250 | <1% | 361 | $8K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,213 | $8K |
| 82947 | <1% | 1,793 | $7K | |
| 82550 | <1% | 767 | $5K | |
| 86140 | <1% | 1,061 | $5K | |
| 73562 | <1% | 48 | $4K | |
| Z9725 | <1% | 77 | $3K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 31 | $3K |
| 82552 | <1% | 200 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 349 | $3K |
| 74019 | <1% | 37 | $3K | |
| 99070 | <1% | 259 | $3K | |
| 86901 | <1% | 856 | $3K | |
| 87581 | <1% | 72 | $3K | |
| 87486 | <1% | 72 | $3K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 72 | $2K |
| 84702 | <1% | 178 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 270 | $2K |
| 87420 | <1% | 472 | $2K | |
| 86900 | <1% | 638 | $2K | |
| 73140 | <1% | 51 | $2K | |
| Z7610 | <1% | 180 | $2K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 278 | $2K |
| 12001 | <1% | 36 | $2K | |
| 90715 | <1% | 39 | $1K | |
| 73590 | <1% | 24 | $1K | |
| 73080 | <1% | 13 | $1K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 82 | $1K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 82 | $947.31 |
| 96367 | <1% | 13 | $943.01 | |
| 84132 | <1% | 211 | $867.08 | |
| 10060 | <1% | 14 | $822.21 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 63 | $805.62 |
| 36415 | Collection of venous blood by venipuncture | <1% | 707 | $755.04 |
| 84295 | <1% | 196 | $732.34 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 87 | $625.00 |
| 84703 | <1% | 58 | $541.15 | |
| 87210 | <1% | 135 | $539.91 | |
| 87147 | <1% | 47 | $489.60 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 46 | $394.27 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 471 | $352.03 |
| 86850 | <1% | 122 | $350.81 | |
| J1815 | Injection, insulin, per 5 units | <1% | 54 | $339.82 |
| 85652 | <1% | 159 | $338.01 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 50 | $285.35 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 44 | $270.80 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 473 | $219.76 |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 18 | $211.86 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 448 | $194.21 |
| 87205 | <1% | 42 | $180.48 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 155 | $177.31 |
| 29125 | <1% | 15 | $172.51 | |
| 87088 | <1% | 25 | $147.85 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 19 | $139.81 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 22 | $104.64 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 12 | $103.09 |
| 87070 | <1% | 12 | $95.48 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 12 | $50.84 |
| 86308 | <1% | 13 | $50.25 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCONFORTI, JAMES (PRESIDENT/CEO)
Parent organizationSUTTER VALLEY HOSPITALS
| Provider | Location | Paid |
|---|---|---|
| Sutter Valley Hospitals | Roseville, CA | $81.16M |
| Sutter Valley Hospitals | Vallejo, CA | $33.28M |
| Sutter Valley Hospitals | Auburn, CA | $15.54M |
| Sutter Valley Hospitals | Jackson, CA | $11.20M |
| Sutter Valley Hospitals | Sacramento, CA | $3.16M |
| Sutter Valley Hospitals | Auburn, CA | $165K |
| Sutter Valley Hospitals | Auburn, CA | $25K |
| Sutter Valley Hospitals | Sacramento, CA | $71.31 |
| Sutter Valley Hospitals | Roseville, CA | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.